Printer Friendly

CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA

 CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID
 ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
 WORCESTER, Mass., Aug. 26 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) and DynaGen, Inc. (NASDAQ: DYGN) today announced the signing of a letter of intent under which CBC will develop and bring to market DynaGen's proprietary rapid test technologies for tuberculosis and other mycobacteria. CBC will acquire rights to certain of DynaGen's rapid test tuberculosis products. CBC plans to adapt the DynaGen technology to CBC's own patented diagnostic formats. Details of the agreement were not disclosed.
 Tuberculosis caused by a mycobacterium that spreads through the air is a leading cause of death in developing countries. The World Health Organization estimates some 20 million people have active tuberculosis, with an annual increase of eight million new cases and three million deaths.
 DynaGen has developed a serological antibody technology that CBC plans to adapt to its latex agglutinography slide instrument assay (SIA) format and its Rapid Test Device formats, as well as an EIA format.
 Commenting on the alliance, Cambridge Biotech President and CEO Dr. Patrick J. Leonard said, "We are pleased to have the opportunity to fill a need for a rapid, accurate screening procedure for tuberculosis, which is treatable in its early stages. Current tests take weeks to confirm a diagnosis. The combination of Cambridge's patented slide technology and DynaGen's proprietary assay technology would yield a result in minutes. We look forward to meeting the challenge of this potentially large screening market, and providing a more effective way to track this dreaded disease."
 Dr. Indu Muni, president and CEO of DynaGen, said, "I am pleased that Cambridge Biotech, with its established presence in the HIV testing marketplace through its line of high quality diagnostic products, is adding DynaGen's tuberculosis testing to its product line. Cambridge Biotech is a successful company with a worldwide reach that provides a tremendous opportunity for introducing our products to the market."
 DynaGen, Inc., a biotechnology company, develops diagnostic and therapeutic products for human and veterinary health care. The company made its initial public offering in August 1990.
 Cambridge Biotech Corporation is a leader in the development of recombinant technology and a major producer of viral diagnostic screening and confirmatory products. The company also develops adjuvants and monoclonal antibodies as the basis for diagnostics, vaccine and therapeutic products for humans and animals.
 -0- 8/26/92
 /CONTACT: Peter P. Hartman, Cambridge Biotech vice president- finance and CFO, 508-797-5777; Jack Barlow, DynaGen senior vice president-business development, 617-491-2527/
 (CBCX DYGN) CO: Cambridge Biotech Corporation; DynaGen, Inc. ST: Massachusetts IN: MTC SU: CON


DH -- NE009 -- 3629 08/26/92 16:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 26, 1992
Words:436
Previous Article:FIRST UNION STRENGTHENS SERVICE TO RESIDENTS OF MIAMI
Next Article:CAMBRIDGE BIOTECH CORPORATION ACQUIRES RIGHTS TO DYNAGEN'S RAPID ANTIBODY TESTS FOR TUBERCULOSIS AND MYCOBACTERIA
Topics:


Related Articles
BIOMIRA CONSOLIDATES MANUFACTURING & MARKETING OF CANCER DIAGNOSTIC KITS IN ADI DIAGNOSTICS; CAMBRIDGE BIOTECH ACQUIRES MINORITY STAKE IN ADI
CAMBRIDGE BIOTECH CORPORATION SIGNS INTENT TO ACQUIRE MINORITY STAKE IN IMMUCELL CORPORATION
CAMBRIDGE BIOTECH ENTERS INTO DEFINITIVE AGREEMENT FOR PURCHASE OF IMMUCELL STOCK; FORMS VENTURE WITH BIONEBRASKA, INC., R&C ENTERPRISES
CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
IMMUCELL SELLS STOCK TO CAMBRIDGE BIOTECH CORPORATION
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH LICENSES ITS STIMULON (TM) ADJUVANT TO UNIVAX BIOLOGICS FOR PRODUCTION OF POLYCLONAL ANTIBODY PRODUCTS
Smith & Nephew, plc to Evaluate DynaGen's OrthoDyn
MorphoSys acquires anti-cancer antibodies from ProChon.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters